Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Mathieu Laversanne, Hyuna Sung...
https://pubmed.ncbi.nlm.nih.gov/38572751/Actively Recruiting
Led by The First Affiliated Hospital of Zhengzhou University · Updated on 2025-04-30
213
Participants Needed
1
Research Sites
52 weeks
Total Duration
Colorectal cancer CRC is a leading cause of cancer-related death worldwide, with a complex development process involving genetic and environmental factors. This research aims to explore the role of brain-gut interactions, particularly neuro-metabolism, in the development and progression of CRC. The study focuses on understanding how brain networks and metabolic processes may influence tumor growth and spread, which could help identify new diagnostic and treatment strategies for CRC. The study uses advanced imaging techniques like 18F-FDG PETCT scans to examine brain metabolism and its connection to CRC. Participants diagnosed with colorectal adenocarcinoma will have their PETCT images collected and analyzed to assess the prognostic value of a neurometabolic network model called BRIDGE. This observational study compares BRIDGEs predictive ability for overall survival with traditional clinical models. Participants will undergo PETCT imaging within 1 to 2 weeks after enrollment, with images anonymized and centrally reviewed for quality. Researchers will collect clinical data and follow patients to evaluate survival outcomes. The primary measure is the area under the curve AUC for BRIDGE in predicting overall survival. The study will run from March 2024 to December 2026, aiming to provide insights into brain metabolisms role in CRC prognosis and support future tailored therapies.
CONDITIONS
Prognostic Value of Neurometabolic Networks in CRC (PVNM-CRC)
Y
Yujie Bai
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The First Affiliated Hospital of Zhengzhou University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 1 to 2 weeks after enrollment
Participants undergo PET/CT imaging to collect brain and tumor metabolic data for analysis.
1 imaging visit
Duration - From enrollment until December 31, 2026
Participants are observed over time to evaluate the prognostic value of neurometabolic networks in colorectal cancer using imaging data and clinical outcomes.
Follow-up assessments as per clinical routine; specific visit schedule not defined
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Freddie Bray, Mathieu Laversanne, Hyuna Sung...
https://pubmed.ncbi.nlm.nih.gov/38572751/Caitlin C Murphy, Timothy A Zaki
https://pubmed.ncbi.nlm.nih.gov/37723270/A Leslie, F A Carey, N R Pratt...
https://pubmed.ncbi.nlm.nih.gov/12081733/Alyssa Schledwitz, Guofeng Xie, Jean-Pierre Raufman
https://pubmed.ncbi.nlm.nih.gov/33998603/The First Affiliated Hospital of Zhengzhou University
Lead Sponsor